Company History

  • August 2015

    Guizhou Taibang entered into a cooperation agreement with Xinjiang Deyuan Bioengineering Co., Ltd., and its controlling shareholder, pursuant to which Xinjiang Deyuan agreed to sell to Guizhou Taibang no less than 500 tonnes of source plasma in batches over the next three years.
  • June 2015

    China Biologic sold 805,000 shares of common stock from its treasury stock in a follow-on offering, and raised net proceeds of approximately $80.6 million.
  • April 2015

    Guizhou Taibang received a one-time special approval from the CFDA to purchase approximately 143 tonnes of source plasma and plasma paste from Xinjiang Deyuan Bioengineering Co., Ltd., for a total consideration of approximately RMB139 million (approximately US$22.6 million).
  • November 2014

    Shandong Taibang received the approval from the Hebei Provincial Health and Family Planning Commission to build two new plasma collection stations in Hebei Province.
FirstPage | PreviousPage | NextPage | LastPage CurrentPageIndex:3 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] 
© 2018 China Biologic Products Holdings, Inc. All Rights Reserved.